Descriptor English: | Cabergoline | ||||||
Descriptor Spanish: |
Cabergolina
| ||||||
Descriptor Portuguese: | Cabergolina | ||||||
Descriptor French: | Cabergoline | ||||||
Entry term(s): |
1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate Cabaser Cabaseril Cabergoline Diphosphate Dostinex FCE 21336 FCE-21336 Galastop |
||||||
Tree number(s): |
D03.132.327.287.131 D03.633.400.439.197 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000077465 | ||||||
Scope note: | An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Antiparkinson Agents Dopamine Agonists |
||||||
Registry Number: | LL60K9J05T | ||||||
CAS Type 1 Name: | Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)- | ||||||
Public MeSH Note: | 2019; CABERGOLINE was indexed under ERGOLINES 1985-2018 |
||||||
History Note: | 2019 (1985) |
||||||
DeCS ID: | 57653 | ||||||
Unique ID: | D000077465 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 2019/01/01 | ||||||
Date of Entry: | 2018/07/09 | ||||||
Revision Date: | 2018/07/03 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds -
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds
|
Cabergoline
- Preferred
FCE 21336
- Narrower
Cabaser
- Narrower
Cabaseril
- Narrower
Dostinex
- Narrower
Galastop
- Narrower
Cabergoline Diphosphate
- Narrower
Concept UI |
M0136060 |
Scope note | An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. |
Preferred term | Cabergoline |
Entry term(s) |
1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea |
Concept UI |
M0136057 |
Preferred term | FCE 21336 |
Entry term(s) |
FCE-21336 |
Concept UI |
M0136055 |
Preferred term | Cabaser |
Concept UI |
M000640795 |
Preferred term | Cabaseril |
Concept UI |
M000640796 |
Preferred term | Dostinex |
Concept UI |
M0136059 |
Preferred term | Galastop |
Concept UI |
M0322534 |
Preferred term | Cabergoline Diphosphate |
Entry term(s) |
1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey